CA-BEHAVIOSEC
31.5.2019 15:02:03 CEST | Business Wire | Press release
BehavioSec, the first vendor to pioneer behavioral biometrics, is attending Money20/20 Europe on June 3-5, 2019 in Amsterdam, Netherlands at the Amsterdam RAI. Money20/20 focuses on the mission of creating a simpler, fairer, faster and more inclusive financial system for individuals, businesses and society as a whole, bringing together more than 350 speakers to deliver the next frontier of Financial Services. BehavioSec CEO Neil Costigan will join the panel discussion, “The Changing Nature of Attacks and Attackers,” where he will discuss cybersecurity and risk management in an age where online commerce and trust are threatened by cybercrime threats continually bypassing traditional password authentication and anti-fraud measures.
Money20/20 attendees can visit BehavioSec at booth H92 throughout the event. BehavioSec will meet with customers and industry partners, brief media and analysts and present demos of the company’s Behavioral Biometrics Software Platform . Already in use with some of the biggest global brands in FinTech and financial services, BehavioSec’s software provides continuous online authentication of account holders by analyzing their unique physical behaviors, like typing patterns, cursor movements and touchscreen inputs.
“Traditional, one-time authentication measures like thumbprints and passwords can no longer protect and enable digital transformation in the financial services sector,” said Costigan. “With today’s constantly evolving attacks bypassing even once reliable multi-factor authentication methods, financial service organizations must find new ways to prevent fraud and cyber attacks without slowing down usability and functionality. Presenting at Money20/20 gives us the opportunity to show the success of behavioral biometrics in combating account takeover fraud in this new threat landscape.”
Join BehavioSec’s Neil Costigan at the following session:
|
What: |
The Changing Nature of Attacks and Attackers |
|
|
Who: |
Neil Costigan, CEO, BehavioSec (Speaker) | |
| Dr. Yinglian Xie, Co-Founder and CEO, DataVisor (Speaker) | ||
| Max Laemmle, Founder and CEO, Fraugster Limited (Speaker) | ||
| Andrew Jamieson, Technology & Security Director, UL (Moderator) | ||
|
When: |
Wednesday, June 5, 2019 from 14:10 p.m. to 14:50 p.m. CEST | |
|
Where: |
Industry Transmutation Stage at RAI Amsterdam, Amsterdam, Netherlands |
As CEO of BehavioSec, Costigan leads the company’s work delivering innovative behavioral biometric technology protecting consumer transactions, payments and financial firms from fraud and theft. He has more than 25 years’ of entrepreneurial and technical leadership experience in venture-backed startups, and global technology corporations spanning the U.S., and EU. A cryptographer by training, his career expanded to include software development, executive leadership and entrepreneurship. He holds an extensive portfolio of patents and serves as Principal Investigator for BehavioSec’s U.S. DOD DARPA projects.
Prior to BehavioSec, Costigan was VP for R&D at Smart Card manufacturer Gemplus (now Gemalto) and Co-founder/CTO at PKI specialists Celo Communications (Celo). Neil holds a PhD (2009) for his thesis on Elliptic Curve Cryptography on Modern Processor Architectures and has developed a number of commercial security applications. He frequently presents and presents on innovation, cryptography and network security.
Follow BehavioSec for more details and the latest in behavioral biometrics technology:
About BehavioSec
BehavioSec is the first vendor to pioneer behavioral biometrics. The company’s Behavioral Biometrics Platform is widely deployed across Global 2000 companies for its proven ability to dramatically reduce account fraud and data theft. Founded in 2008 out of groundbreaking academic research, BehavioSec technology allows companies to continuously verify digital identities with superior precision, in real-time. Strengthened with the leadership of serial entrepreneurs and experienced industry professionals, the BehavioSec team now spans the world, providing security while preserving a rich digital experience throughout web and mobile apps. BehavioSec is the only enterprise-grade vendor used in global deployments with some of the largest companies, reducing manual review whilst safeguarding millions of users and billions of transactions. BehavioSec investors include Forgepoint Capital, Cisco, ABN AMRO, Conor Ventures and Octopus Ventures. BehavioSec is headquartered in San Francisco, CA and has global operations throughout Europe and Asia Pac. For more information, visit www.behaviosec.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190531005032/en/
Contact:
Media Contact: Savannah Young +1 (703) 877-8111 pr@behaviosec.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom